Global breast biopsy devices market is forecasted to generate a revenue of $1.4 billion by 2023, P&S Market Research.The growth is mainly led by product and technological innovations, increasing incidence of breast cancer cases, rising propensity for minimally invasive surgeries, and mounting number of breast cancer screening programs.

On the basis of the procedure conducted for breast biopsy, the market is categorized into vacuum-assisted, core needle, fine needle aspiration, and surgical biopsy. Vacuum-assisted biopsies have been accounting for the largest share in the breast biopsy devices market till now. It is also expected to be the fastest growing category during the forecast period. This can be mainly attributed to its various advantages, such as its ability to precisely locate the area of abnormality using imaging guidance, so that samples are removed only from the region of interest.

Different types of imaging modalities are used while performing breast biopsy procedure, such as mammography guided stereotactic biopsy, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and several others. Among these, Mammography guided stereotactic biopsy has been holding the largest share in the breast biopsy devices market till now, as it is a minimally invasive procedure and the needle used does not distort the breast tissue. However, ultrasound guided biopsy is expected to be the fastest growing imaging modality during the forecast period.

Request to Get the Sample Pages at:

Hospitals, diagnostic centers, and other healthcare providers constitute the end-user base in the breast biopsy devices market. Diagnostic centers have been the largest end user in the breast biopsy devices market till now. However, as hospitals are witnessing increasing demand for advanced healthcare facilities and growing healthcare infrastructure, the category is expected to be the fastest growing end-user during the forecast period.

During the forecast period, the breast biopsy devices industry is expected to witness the fastest growth in in Asia-Pacific (APAC), owing to growing geriatric population, increasing prevalence of breast cancer, growing awareness about breast cancer, rising healthcare expenditure, per capita income, and increasing research in breast biopsy devices in the region. According to National Institute of Cancer Prevention and Research, breast cancer is the most common cancer in women in India and accounts for about a quarter of all cancers in women in Indian cities, and the average age for breast cancer in India is almost a decade lower than that in the West.

Make Enquiry Before Buying the Report:

Breast biopsy surgeries are cheaper in India and they are also witnessing an increase in the research and development for the treatment of breast cancer, which is ultimately propelling the growth of the breast biopsy devices market in the region. For instance, a team of researchers from Tohoku University, in January 2016, developed a new method to detect breast cancer by combining a mammogram with an ultrasound in a procedure that appears to be more accurate than mammogram testing alone.

Some of the other major players operating in the breast biopsy devices market include Danaher Corporation, Argon Medical Devices Inc., Becton, Dickinson and Company, Sterylab S.R.L., Scion Medical Technologies LLC, Planmed Oy, Medtronic plc, and Cook Medical LLC.